Kamada Ltd. (KMDA)
USD 5.8
(0.87%)
USD 5.8
(0.87%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 8.74 Million USD | -57.53% |
| 2022 | 20.6 Million USD | -15.41% |
| 2021 | 24.35 Million USD | 393.06% |
| 2020 | 4.93 Million USD | -14.06% |
| 2019 | 5.74 Million USD | 349.69% |
| 2018 | 1.27 Million USD | -35.58% |
| 2017 | 1.98 Million USD | 11.71% |
| 2016 | 1.77 Million USD | 844.68% |
| 2015 | 188 Thousand USD | -97.49% |
| 2014 | 7.49 Million USD | -53.8% |
| 2013 | 16.21 Million USD | -32.76% |
| 2012 | 24.11 Million USD | 7.03% |
| 2011 | 22.53 Million USD | -2.79% |
| 2010 | 23.17 Million USD | 10.39% |
| 2009 | 20.99 Million USD | 3.33% |
| 2008 | 20.32 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 8.66 Million USD | -0.95% |
| 2024 Q2 | 8.53 Million USD | -1.23% |
| 2023 Q2 | 21.22 Million USD | -6.63% |
| 2023 FY | 8.74 Million USD | -57.53% |
| 2023 Q4 | 8.74 Million USD | 49.43% |
| 2023 Q1 | 22.72 Million USD | 10.32% |
| 2023 Q3 | 5.85 Million USD | -72.41% |
| 2022 Q3 | 21.93 Million USD | -5.19% |
| 2022 Q1 | 24.09 Million USD | -1.06% |
| 2022 Q2 | 23.13 Million USD | -3.98% |
| 2022 FY | 20.6 Million USD | -15.41% |
| 2022 Q4 | 20.6 Million USD | -6.09% |
| 2021 Q3 | 4.51 Million USD | -2.17% |
| 2021 Q1 | 4.65 Million USD | -5.73% |
| 2021 FY | 24.35 Million USD | 393.06% |
| 2021 Q2 | 4.61 Million USD | -0.86% |
| 2021 Q4 | 24.35 Million USD | 439.24% |
| 2020 Q3 | 4.99 Million USD | -3.68% |
| 2020 Q2 | 5.18 Million USD | -0.12% |
| 2020 Q1 | 5.19 Million USD | -9.62% |
| 2020 Q4 | 4.93 Million USD | -1.16% |
| 2020 FY | 4.93 Million USD | -14.06% |
| 2019 FY | 5.74 Million USD | 349.69% |
| 2019 Q1 | 6.05 Million USD | 374.02% |
| 2019 Q2 | 5.91 Million USD | -2.44% |
| 2019 Q3 | 6.05 Million USD | 2.37% |
| 2019 Q4 | 5.74 Million USD | -5.01% |
| 2018 Q4 | 1.27 Million USD | -12.76% |
| 2018 FY | 1.27 Million USD | -35.58% |
| 2018 Q3 | 1.46 Million USD | -8.72% |
| 2018 Q2 | 1.6 Million USD | -11.33% |
| 2018 Q1 | 1.81 Million USD | -8.77% |
| 2017 Q3 | 2.1 Million USD | 6.32% |
| 2017 Q2 | 1.97 Million USD | 11.94% |
| 2017 Q1 | 1.76 Million USD | -0.51% |
| 2017 FY | 1.98 Million USD | 11.71% |
| 2017 Q4 | 1.98 Million USD | -5.66% |
| 2016 Q2 | 1.92 Million USD | 112.68% |
| 2016 Q3 | 1.91 Million USD | -0.57% |
| 2016 Q4 | 1.77 Million USD | -7.4% |
| 2016 Q1 | 907 Thousand USD | 382.45% |
| 2016 FY | 1.77 Million USD | 844.68% |
| 2015 Q4 | 188 Thousand USD | -97.56% |
| 2015 Q1 | 7.41 Million USD | -1.08% |
| 2015 Q2 | 7.92 Million USD | 6.92% |
| 2015 FY | 188 Thousand USD | -97.49% |
| 2015 Q3 | 7.71 Million USD | -2.7% |
| 2014 Q3 | 15.89 Million USD | -5.58% |
| 2014 Q1 | 16.36 Million USD | 0.91% |
| 2014 Q2 | 16.83 Million USD | 2.89% |
| 2014 FY | 7.49 Million USD | -53.8% |
| 2014 Q4 | 7.49 Million USD | -52.87% |
| 2013 FY | 16.21 Million USD | -32.76% |
| 2013 Q3 | 26.31 Million USD | 3.33% |
| 2013 Q2 | 25.46 Million USD | 1.87% |
| 2013 Q1 | 24.99 Million USD | 3.65% |
| 2013 Q4 | 16.21 Million USD | -38.37% |
| 2012 FY | 24.11 Million USD | 7.03% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | 24.11 Million USD | 0.0% |
| 2011 FY | 22.53 Million USD | -2.79% |
| 2010 FY | 23.17 Million USD | 10.39% |
| 2009 FY | 20.99 Million USD | 3.33% |
| 2008 FY | 20.32 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Theratechnologies Inc. | 58.96 Million USD | 85.163% |
| Harrow Health, Inc. | 190.5 Million USD | 95.407% |
| Dynavax Technologies Corporation | 256.91 Million USD | 96.595% |
| Biofrontera Inc. | 5.39 Million USD | -62.048% |
| Cronos Group Inc. | 2.53 Million USD | -244.457% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -1338.978% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 98.777% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 75.913% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -645.86% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | 52.525% |
| Radius Health, Inc. | 365.31 Million USD | 97.605% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -59.582% |
| DURECT Corporation | 20.74 Million USD | 57.828% |
| ProPhase Labs, Inc. | 21.38 Million USD | 59.079% |
| Safety Shot Inc | 1.54 Million USD | -464.825% |
| Phibro Animal Health Corporation | 525.45 Million USD | 98.335% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -230.468% |
| Alvotech | 1.07 Billion USD | 99.186% |
| Assertio Holdings, Inc. | 40.91 Million USD | 78.615% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 78.932% |
| Rockwell Medical, Inc. | 13.43 Million USD | 34.899% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -1230.23% |
| Procaps Group S.A. | 285.93 Million USD | 96.94% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | 48.347% |
| SCYNEXIS, Inc. | 15.08 Million USD | 41.983% |
| Aytu BioPharma, Inc. | 15.12 Million USD | 42.171% |
| Viatris Inc. | 18.12 Billion USD | 99.952% |
| OptiNose, Inc. | 131.74 Million USD | 93.359% |
| SIGA Technologies, Inc. | 1.46 Million USD | -497.605% |
| Tilray Brands, Inc. | 387.31 Million USD | 97.741% |
| PetIQ, Inc. | 468.3 Million USD | 98.132% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -1230.23% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 97.958% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Alimera Sciences, Inc. | 67.39 Million USD | 87.019% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 98.702% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -704.361% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 92.67% |
| Journey Medical Corporation | 17.73 Million USD | 50.654% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -5.708% |
| Alpha Teknova, Inc. | 30.45 Million USD | 71.275% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | -319.214% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 93.289% |
| PainReform Ltd. | 86 Thousand USD | -10073.241% |
| Cosmos Health Inc. | 12.42 Million USD | 29.58% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | 75.274% |
| TherapeuticsMD, Inc. | 8 Million USD | -9.294% |
| Embecta Corp. | 1.63 Billion USD | 99.466% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -14528.701% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 98.507% |
| Incannex Healthcare Limited | 373 Thousand USD | -2245.573% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -746.855% |
| Shineco, Inc. | 29.65 Million USD | 70.499% |
| Procaps Group, S.A. | 285.93 Million USD | 96.94% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 97.225% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 91.147% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 98.582% |
| Alvotech | 1.07 Billion USD | 99.186% |
| Hempacco Co., Inc. | 13.72 Million USD | 36.253% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | 85.994% |
| Bright Green Corporation | 1.85 Million USD | -372.463% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 98.383% |
| Indivior PLC | 281.6 Million USD | 96.893% |
| Evoke Pharma, Inc. | 5 Million USD | -74.98% |
| Flora Growth Corp. | 3.67 Million USD | -138.262% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -746.855% |
| Evolus, Inc. | 126.54 Million USD | 93.086% |
| HUTCHMED (China) Limited | 86.13 Million USD | 89.842% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 98.597% |
| Akanda Corp. | 3.99 Million USD | -118.791% |